Available Technologies
# of Displayed Technologies: 10 / 17
Applied Category Filter (Click To Remove): Peptides/Proteins
Breakthrough In Delivery: Expanding Access to Intracellular Targets for Next-Generation Therapies
TS-072004 — Empower your pipeline with a versatile platform for efficient, customizable biomolecule transport.
Overview
Intracellular delivery remains a persistent challenge in drug delivery, gene editing, and biotechnology. Pharmaceutical and biotech companies lose valuable opportunities when promising drugs and biologics cannot reach their intended targets inside cells, limiting product effectiveness and m…
- College: College of Arts & Sciences
- Inventors: Bong, Dennis
- Licensing Officer: Panic, Ana
Revolutionizing Corneal Repair: Advanced MG53-Based Treatment for Enhanced Ocular Health
TS-066878 — New and more effective treatments for corneal injuries.
Current treatments for corneal injuries often have side effects that can compromise vision, highlighting the need for a new method that enhances ocular tissue repair without such drawbacks.
The Need
Injuries to the cornea can lead to severe pain, infection, and vision loss due to scarring and abno…
- College: College of Optometry
- Inventors: Chandler, Heather; Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Cell-Penetrating Peptides: Revolutionizing Intracellular Delivery
TS-066751 —
In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…
- College: College of Arts & Sciences
- Inventors: Pei, Dehua
- Licensing Officer: Dahlman, Jason "Jay"
MG53: Enhancing Tissue Performance and Repairing Damaged Tissue
TS-066191 — , T2019-164, T2020-002, T2020-159, T2020-222: Using rhMG53 to treat conditions involving damaged tissue, including corneal repair, hepatic tissue injury, inflammatory bowel disease, and other tissue injury.
The Need
While MG53 is naturally present in skeletal and cardiac muscle, its levels are often insufficient to optimize tissue performance. Current treatments leveraging exogenous MG53 are therapeutically ineffective for conditions like multiple sclerosis, viral infections, radiation-induced tissue …
- College: College of Medicine (COM)
- Inventors: Ma, Jianjie; Tan, Tao; Zhu, Hua
- Licensing Officer: Schultz, Teri
Targeting Telomerase to Treat Ocular Neovascular Disorders
TS-065809 — Therapeutic strategies for treating ocular neovascular disorders by targeting telomerase.
Choroidal neovascularization (CNV) is the principal driver of blindness in neovascular age-related macular degeneration (nvAMD). Abnormal blood vessel growth beneath the macular leads to retinal damage and severe vision loss. Discovering the involvement of VEGF in the underlying mechanisms driving …
- College: College of Medicine (COM)
- Inventors: Kerur, Nagaraj
- Licensing Officer: Willson, Christopher
Multimeric Notch ligands based on IgM-like fusion molecular structures for activation of ligand-specific Notch signaling
TS-064248 —
The Notch signaling pathway is important in immune cell differentiation and maturation. As a result, it has been shown that Notch receptor signaling can promote or suppress adaptive immune responses depending on the particular ligands and receptors involved. A set of native protein-inspired biolog…
- College: OSU Wexner Medical Center
- Inventors: Dikov, Mikhail; Carbone, David; Goruganthu, Uttam Lakshmi Mounika; Tchekneva, Elena
- Licensing Officer: Willson, Christopher
A Breakthrough in Central Nervous System Repair
TS-062739 — Method to program pericytes for axon regeneration and spinal cord injury repair.
In the realm of central nervous system (CNS) repair, a critical need arises for innovative treatments that not only address the physical aspects of injury but also tackle the associated phychopathology. Understanding the cellular processes that occur after spinal cord injury (SCI) that are detrimen…
- College: College of Medicine (COM)
- Inventors: Tedeschi, Andrea
- Licensing Officer: Willson, Christopher
Bi-specific T-Cell Engagers as Anti-cancer Therapeutics
TS-062677 — Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020, or nearly one in six deaths. The most common cancers are breast, lung, colon and rectum and prostate cancers.
The Need
Current cancer treatments mainly rely on chemotherapy, radiation, surgery and bon…
- College: College of Medicine (COM)
- Inventors: Caligiuri, Michael; Chan, Wing; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Genetically Encodable Cyclic Cell-Penetrating Peptides and Uses Thereof
TS-062617 — The Need: In today's fast-paced world, effective drug delivery remains a paramount challenge in achieving therapeutic outcomes. Pharmaceutical industries and researchers are in pursuit of innovative technologies to overcome cellular barriers and deliver therapeutic agents precisely. Addressing t…
- College: College of Arts & Sciences
- Inventors: Pei, Dehua
- Licensing Officer: Dahlman, Jason "Jay"
Purification of apoproteins and general methods for protein purification
TS-062540 — General methods for purifying proteins that can be used in various applications such as targeted drug delivery, bioimaging, and hemolysis treatment.
The Need
Novel protein and apoprotein purification strategies are valuable tools with a wide variety of medical and research applications. While there are existing techniques for protein and apoprotein purification, some of these have flaws such as the use of harsh denaturants, highly flammable sol…
- College: College of Engineering (COE)
- Inventors: Susin Pires, Ivan; Cabrales, Pedro; Palmer, Andre
- Licensing Officer: Schworer, Adam
